203 related articles for article (PubMed ID: 27388928)
1. Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model.
Hwang TJ; LaMattina JL
JAMA Oncol; 2016 Sep; 2(9):1125-6. PubMed ID: 27388928
[No Abstract] [Full Text] [Related]
2. Limits on Medicare's ability to control rising spending on cancer drugs.
Bach PB
N Engl J Med; 2009 Feb; 360(6):626-33. PubMed ID: 19176475
[No Abstract] [Full Text] [Related]
3. Leap of Faith--Medicare's New Physician Payment System.
Oberlander J; Laugesen MJ
N Engl J Med; 2015 Sep; 373(13):1185-7. PubMed ID: 26398067
[TBL] [Abstract][Full Text] [Related]
4. Medicare's new payment system.
Internist; 1992 Jan; 33(1):37. PubMed ID: 10116104
[No Abstract] [Full Text] [Related]
5. Medicare's proposed CY 2011 physician payment rule--keep watch!
Freeman J
Iowa Med; 2010; 100(5):8-9. PubMed ID: 21186741
[No Abstract] [Full Text] [Related]
6. Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.
Polite BN; Ward JC; Cox JV; Morton RF; Hennessy J; Page RD; Conti RM
J Oncol Pract; 2014 Nov; 10(6):357-62. PubMed ID: 25398955
[TBL] [Abstract][Full Text] [Related]
7. Refining Medicare Volume Performance Standards.
Ginsburg PB
Inquiry; 1993; 30(3):260-4. PubMed ID: 8406783
[TBL] [Abstract][Full Text] [Related]
8. Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?
Gordan L; Grogg A; Blazer M; Fortner B
J Oncol Pract; 2017 Feb; 13(2):e139-e151. PubMed ID: 28029298
[TBL] [Abstract][Full Text] [Related]
9. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
Mailankody S; Prasad V
JAMA; 2016 Jul; 316(3):271-2. PubMed ID: 27149663
[No Abstract] [Full Text] [Related]
10. Paying for Cancer Drugs That Prove Their Benefit.
Frank RG; Emanuel EJ
JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
[No Abstract] [Full Text] [Related]
11. Opposition to Value-Based Cancer Care-Interests of Patients or Conflicts of Interest?
Goldstein DA
Mayo Clin Proc; 2016 Dec; 91(12):1842-1843. PubMed ID: 27916159
[No Abstract] [Full Text] [Related]
12. Medicare and drug pricing.
Iglehart JK
N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
[No Abstract] [Full Text] [Related]
13. Orals in the bundle: a policy framework.
Feldman RL; Desmarais MP; Muller JS
Clin J Am Soc Nephrol; 2013 Jun; 8(6):1043-7. PubMed ID: 23599409
[TBL] [Abstract][Full Text] [Related]
14. Medicare challenges and solutions--reimbursement issues in treating the patient with colorectal cancer.
Kaa K
J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S19-26. PubMed ID: 17713991
[TBL] [Abstract][Full Text] [Related]
15. Reimbursing Wisely? CMS's Trial of Medicare Part B Drug Payment Reform.
Schrag D
N Engl J Med; 2016 Jun; 374(22):2101-5. PubMed ID: 27248616
[No Abstract] [Full Text] [Related]
16. Medicare's hidden price tag.
Scala-Foley MA; Caruso JT; Bader E; Reinhard SC
Am J Nurs; 2004 May; 104(5):32-3, 35. PubMed ID: 15166710
[No Abstract] [Full Text] [Related]
17. The financial impact of the sequester cut to Medicare Part B drug reimbursement in community oncology.
Gordan L; Schaedig C; Weidner S
Am J Manag Care; 2018 Oct; 24(12 Spec No.):SP515-SP516. PubMed ID: 30550250
[No Abstract] [Full Text] [Related]
18. Medicare's fee changes: how will you fare?
Preston SH
Med Econ; 1998 Jan; 75(2):115, 119-22, 128-30. PubMed ID: 10175883
[No Abstract] [Full Text] [Related]
19. Physician payment reform: past and future.
Epstein AM; Blumenthal D
Milbank Q; 1993; 71(2):193-215. PubMed ID: 8510600
[TBL] [Abstract][Full Text] [Related]
20. Addressing cost-related nonadherence to oral anticancer medications through health policy reform: Challenges and opportunities.
Jazowski SA; Dusetzina SB
Cancer; 2020 Aug; 126(16):3613-3616. PubMed ID: 32438468
[No Abstract] [Full Text] [Related]
[Next] [New Search]
